Centers for Disease Control and Prevention. National diabetes statistics report 2022. https://www.cdc.gov/diabetes/php/data-research/index.html. Accessed Feb 25, 2025.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–28.

Article  PubMed Central  Google Scholar 

Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20:6–12.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association. Standards of care in diabetes—2023. Diabetes Care. 2023;46:S1–291.

Article  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR, et al. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46:S140–57.

Article  CAS  PubMed  Google Scholar 

American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48:S181–206.

Article  Google Scholar 

Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018—a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487–93.

Article  CAS  PubMed  Google Scholar 

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701.

Article  PubMed  PubMed Central  Google Scholar 

Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2019 executive summary. Endocr Pract. 2019;25:69–100.

Article  PubMed  Google Scholar 

Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clin Diabetes. 2020;38:390–402.

Article  PubMed  PubMed Central  Google Scholar 

Divino V, Boye KS, Lebrec J, DeKoven M, Norrbacka K. GLP-1 RA treatment and dosing patterns among type 2 diabetes patients in six countries: a retrospective analysis of pharmacy claims data. Diabetes Ther. 2019;10:1067–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Divino V, DeKoven M, Khan FA, Boye KS, Sapin H, Norrbacka K. GLP-1 RA treatment patterns among type 2 diabetes patients in five European countries. Diabetes Ther. 2017;8:115–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weiss T, Carr RD, Pal S, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337–45.

Article  PubMed  PubMed Central  Google Scholar 

Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46:100–9.

Article  CAS  PubMed  Google Scholar 

Alsugair HA, Alshugair IF, Alharbi TJ, Bin Rsheed AM, Tourkmani AM, Al-Madani W. Weekly semaglutide vs liraglutide efficacy profile: a network meta-analysis. Healthcare (Basel). 2021;9:1125.

Article  PubMed  Google Scholar 

Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG. Real-world effectiveness analysis of switching from liraglutide or dulaglutide to semaglutide in patients with type 2 diabetes mellitus: the retrospective REALISE-DM study. Diabetes Ther. 2021;12:527–36.

Article  CAS  PubMed  Google Scholar 

Kassem S, Khalaila B, Stein N, Saliba W, Zaina A. Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data. Diabetes Obes Metab. 2024;26:4646–52.

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

Article  CAS  PubMed  Google Scholar 

Newsome P, Sanyal A, Kliers I, et al. Phase 3 ESSENCE trial: semaglutide in metabolic dysfunction associated steatohepatitis (MASH). The Liver Meeting; November 15–19, 2024; San Diego, CA. (AASLD abstract 5018), 2024.

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109–21.

Article  CAS  PubMed  Google Scholar 

Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther. 2015;32:341–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melzer-Cohen C, Chodick G, Husemoen LLN, Rhee N, Shalev V, Karasik A. A retrospective database study of liraglutide persistence associated with glycemic and body weight control in patients with type 2 diabetes. Diabetes Ther. 2019;10:683–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uzoigwe C, Noone J, Liang Y, Ali SN, Gamble C. Increased healthcare resource use and costs after discontinuation of liraglutide in patients with type 2 diabetes from a commercial- and Medicaid-insured claims database. Diabetes Ther. 2022;13:1861–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buysman EK, Sikirica MV, Thayer SW, Bogart M, DuCharme MC, Joshi AV. Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutide. J Comp Eff Res. 2018;7:89–100.

Article  PubMed  Google Scholar 

Crabtree TSJ, Adamson K, Reid H, et al. Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2022;24:1398–401.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lingvay I, Kirk AR, Lophaven S, Wolden ML, Shubrook JH. Outcomes in GLP-1 RA-experienced patients switching to once-weekly semaglutide in a real-world setting: the retrospective, observational EXPERT study. Diabetes Ther. 2021;12:879–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goncalves E, Bell DS. Efficacy of semaglutide versus liraglutide in clinical practice. Diabetes Metab. 2020;46:515–7.

Article  CAS  PubMed  Google Scholar 

Evans M, Berry S, Malkin SJP, Hunt B, Sharma A. Evaluating the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.8 mg: a health economic analysis in the UK. Diabetes Ther. 2023;14:1005–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain AB, Ali A, Gorgojo Martínez JJ, et al. Switching between GLP-1 receptor agonists in clinical practice: expert consensus and practical guidance. Int J Clin Pract. 2021;75:e13731.

Article  PubMed  Google Scholar 

American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S98-110.

Article  Google Scholar 

Beyrer J, Manjelievskaia J, Bonafede M, et al. Validation of an international classification of disease, 10th revision coding adaptation for the Charlson comorbidity index in United States healthcare claims data. Pharmacoepidemiol Drug Saf. 2021;30:582–93.

Article  PubMed  PubMed Central  Google Scholar 

Glasheen WP, Renda A, Dong Y. Diabetes complications severity index (DCSI)-update and ICD-10 translation. J Diabetes Complicat. 2017;31:1007–13.

Article  Google Scholar 

Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13:273–7.

Article  PubMed